Literature DB >> 12952760

Topical pimecrolimus in the treatment of seborrheic dermatitis.

Isaac Brownell1, Long T Quan, Sylvia Hsu.   

Abstract

Seborrheic dermatitis is a chronic inflammatory disease that mainly affects seborrheic areas of skin. An inflammatory response to the yeast Pityrosporum ovale has been thought to be important in the etiology of the condition. Therefore, topical antifungals and corticosteroids have been the mainstay of treatment. The recent development of topical macrolactam immunomodulators has offered a useful, safe alternative to corticosteroids in the treatment of various inflammatory skin disorders. We report successful treatment of seborrheic dermatitis with pimecrolimus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952760

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  3 in total

1.  Treatment of seborrheic dermatitis: comparison of sertaconazole 2 % cream versus pimecrolimus 1 % cream.

Authors:  M Goldust; E Rezaee; R Raghifar
Journal:  Ir J Med Sci       Date:  2013-05-29       Impact factor: 1.568

2.  Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.

Authors:  Grace K Kim; James Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-02

3.  Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients.

Authors:  Byung-Soo Kim; Su-Han Kim; Moon-Bum Kim; Chang-Keun Oh; Ho-Sun Jang; Kyung-Sool Kwon
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.